| Pharmacologic Class | First to be Marketed in the U.S. | FDA Approved Indication | 11th Edition Reference |
|---|---|---|---|
| C1 inhibitor | C1 inhibitor (Cinryze) | Routine prophylaxis against angioedema attacks in patients with hereditary angioedema | page 1405 |
| CXCR4 chemokine receptor inhibitor | plerixa (Mozobil) | Mobilization of granulocyte-colony stimulating factor induced hematopoietic stem cells to the peripheral blood prior to collection | page 1274 |
| peripherally acting ยต-opioid receptor antagonist | alvimopan (Entereg) | Acceleration of the time to gastrointestinal recovery following bowel surgery | pages 561-562 |
| methylnaltrexone (Relistor) | Treatment of opioid-induced constipation | ||
| thrombopoietin receptor agonist | eltrombopag (Promacta) | Treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura | pages 1441-1442 |
| romiplostim (Nplate) |
7 years ago
Posts
No comments:
Post a Comment
Add your comment